Back to Search
ROBERT BRADBURY, DMD
DMD
General Practice Dentistry
NPI: 1780755595Individual
Specialties, Licenses & Credentials
General Practice DentistryPrimary
Dentist — General Practice
Code: 1223G0001X
005955(CT)
Research & Publications (20)
Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
PMID 17825081·Diabetes Obes Metab·2008
6-review
Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an 'orphan' area? A retrospective case-control study.
PMID 19220548·Intern Med J·2009
4-observational
Comparative toxicity of essential oils of Litsea pungens and Litsea cubeba and blends of their major constituents against the cabbage looper, Trichoplusia ni.
PMID 19422220·J Agric Food Chem·2009
4-observational
Antiretroviral adherence in rural Zambia: the first year of treatment availability.
PMID 19346397·Am J Trop Med Hyg·2009
8-other
Transition from vesicles to small nanometer scaled vesicles, arising from the manipulation of curvature in dialkyl chain cationic/nonionic surfactant mixed aggregates by the addition of straight chain alkanols.
PMID 19256459·Langmuir·2009
8-other
A microbiological survey of selected Alberta-grown fresh produce from farmers' markets in Alberta, Canada.
PMID 19350990·J Food Prot·2009
7-preclinical
Phaeochromocytoma and mixed corticomedullary tumour - a rare cause of Cushing's syndrome and labile hypertension in a primigravid woman postpartum.
PMID 17868399·Clin Endocrinol (Oxf)·2008
5-case
Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
PMID 18811887·Respirology·2008
8-other
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
PMID 18313293·Bioorg Med Chem Lett·2008
7-preclinical
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
PMID 18061446·Bioorg Med Chem Lett·2008
7-preclinical
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
PMID 17869514·Bioorg Med Chem Lett·2007
7-preclinical
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
PMID 16806916·Bioorg Med Chem Lett·2006
7-preclinical
Why do we still use stepwise modelling in ecology and behaviour?
PMID 16922854·J Anim Ecol·2006
6-review
Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome.
PMID 18632493·Support Cancer Ther·2006
8-other
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
PMID 16380259·Bioorg Med Chem Lett·2006
7-preclinical
Comparative toxicity of Rosmarinus officinalis L. essential oil and blends of its major constituents against Tetranychus urticae Koch (Acari: Tetranychidae) on two different host plants.
PMID 16470541·Pest Manag Sci·2006
4-observational
Depletion, degradation, and recovery potential of estuaries and coastal seas.
PMID 16794081·Science·2006
7-preclinical
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
PMID 16055332·Bioorg Med Chem Lett·2005
7-preclinical
Brain size and resource specialization predict long-term population trends in British birds.
PMID 16191644·Proc Biol Sci·2005
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 18 N MAIN ST, SECOND FLOOR
WEST HARTFORD, CT 06107 - Phone
- (860) 561-3050
Quick Facts
- NPI
- 1780755595
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile